The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Nitazoxanide in the treatment of viral gastroenteritis: a randomized double‐blind placebo‐controlled clinical trial
Abstract
Summary: Background: Enteric viruses including noroviruses and rotavirus are leading causes of diarrhoeal disease and gastroenteritis worldwide, and there is no effective treatment. Aim: To evaluate nitazoxanide, a thiazolide anti‐infective agent, in treating viral gastroenteritis in adults and adolescents. Methods: 50 out‐patients at least 12 years of age (mean 33.5 years) presenting with diarrhoea and stool‐positive by enzyme‐linked immunosorbent assay for norovirus, rotavirus or adenovirus were enrolled in a double‐blind, placebo‐controlled clinical trial. Patients were randomly assigned either nitazoxanide 500 mg or placebo twice daily for 3 days. The primary end point was time from first dose to resolution of symptoms. Analysis was modified intent‐to‐treat for 45 patients, excluding five patients with other identified enteropathogens at baseline. Results: The median time from first dose to resolution of symptoms was 1.5 days (IQR: 0.5–2.5) for nitazoxanide‐treated patients and 2.5 days (IQR: 1.5–4.5) for the placebo group. Significant reductions in time to resolution of symptoms were observed for all patients analysed (P < 0.0001) and for subsets of patients with rotavirus (P = 0.0052) and norovirus (P = 0.0295). The number of patients with adenovirus (n = 5) was too small to draw any conclusion. No significant adverse events were reported. Conclusions: Nitazoxanide may play an important role in managing viral gastroenteritis in adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy
Infante, R. M., Ericsson, C. D., Jiang, Z.-D., Ke, S., Steffen, R., Riopel, L., Sack, D. A., & Du>Pont, H. L. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00322-7 · Cited by 55
Cited by
Robilotti, E., Deresinski, S., & Pinsky, B. A. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00075-14 · Cited by 589
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Rossignol, J.-F. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.07.014 · Cited by 556
Self-citationHuman norovirus transmission and evolution in a changing world
de Graaf, M., van Beek, J., & Koopmans, M. P. G. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.48 · Cited by 479
Bányai, K., Estes, M. K., Martella, V., & Parashar, U. D. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31128-0 · Cited by 445
Norovirus Gastroenteritis in Immunocompromised Patients
Bok, K., & Green, K. Y. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1207742 · Cited by 358
Metadata
- Authors
- ROSSIGNOL, J. ‐., & EL‐GOHARY, Y. M.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2006-10-27
- Volume
- 24
- Issue
- 10
- Pages
- 1423-1430
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2149272038
- Cited by
- 180
- References
- 1
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nitazoxanide in the treatment of viral gastroenteritis: a randomized double‐blind placebo‐controlled clinical trial. https://app.cochat.ai/papers/10.1111/j.1365-2036.2006.03128.x
- The paper
- ROSSIGNOL, J. ‐., & EL‐GOHARY, Y. M. (2006). Nitazoxanide in the treatment of viral gastroenteritis: a randomized double‐blind placebo‐controlled clinical trial. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2006.03128.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.